摘要 Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating, chronic condition characterized by chronic pelvic pain, urinary urgency, and frequency and is well-known to be associated with a decrease in work productivity, emotional changes, sleep, sexual dysfunction, and mobility. Many metrics of quality of life (QoL) in this patient population have been developed; however, a unified, standardized approach to QoL in these patients has not been determined. The effects of IC/BPS and co-morbid conditions on QoL are described using current validated metrics. Next, data regarding successful treatment of IC/BPS in terms of QoL improvement are reviewed. While QoL is the single most important clinical measure of success in the treatment of patients suffering from IC/BPS, addressing QoL in this patient population remains a significant challenge, as its effects on QoL are highly variable and unable to be differentiated from the effects of comorbid conditions on QoL, including depression, poor sleep, and inability to work. Future studies will need to address treatment efficacy on the basis of IC/BPS specific QoL metrics, and multi-modal assessment and therapy to address comorbid disease will also play an important role in the future to ensure comprehensive management of these patients.
Abstract: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating, chronic condition characterized by chronic pelvic pain, urinary urgency, and frequency and is well-known to be associated with a decrease in work productivity, emotional changes, sleep, sexual dysfunction, and mobility. Many metrics of quality of life (QoL) in this patient population have been developed; however, a unified, standardized approach to QoL in these patients has not been determined. The effects of IC/BPS and co-morbid conditions on QoL are described using current validated metrics. Next, data regarding successful treatment of IC/BPS in terms of QoL improvement are reviewed. While QoL is the single most important clinical measure of success in the treatment of patients suffering from IC/BPS, addressing QoL in this patient population remains a significant challenge, as its effects on QoL are highly variable and unable to be differentiated from the effects of comorbid conditions on QoL, including depression, poor sleep, and inability to work. Future studies will need to address treatment efficacy on the basis of IC/BPS specific QoL metrics, and multi-modal assessment and therapy to address comorbid disease will also play an important role in the future to ensure comprehensive management of these patients.
Vinaya Vasudevan, Robert Moldwin. Addressing quality of life in the patient with interstitial cystitis/bladder pain syndrome[J]. Asian Journal of Urology, 2017, 4(1): 50-54.
Vinaya Vasudevan, Robert Moldwin. Addressing quality of life in the patient with interstitial cystitis/bladder pain syndrome. Asian Journal of Urology, 2017, 4(1): 50-54.
[1] Barofsky I. Can quality or quality of life be defined? Qual Life Res 2012;21:625e31. [2] Felce D, Perry J. Quality of life:its definition and measurement. Res Dev Disabil 1995;16:51e74. [3] WHOQOL. Measuring quality of life. Programme on mental health:division of mental health and prevention of substance abuse. World Health Organization; 1997. p. 1e10. [4] Michael YL, Kawachi I, Stampfer MJ, Colditz GA, Curhan GC. Quality of life amonth women with interstitial cystitis. J Urol 2000;164:423e7. [5] Held PJ, Hanno PM, Wein AJ. Epidemiology of interstitial cystitis:2. In:Interstitial cystitis. New York:Springer-Verlag; 1990. p. 29. [6] Goin JE, Olaleye D, Peters KM, Steinert B, Habicht K, Wynant G. Psychometric analysis of the University of Wisconsin Interstitial Cystitis Scale:implications for use in randomized clinical trials. J Urol 1998;159:1085e90. [7] Oleary MP, Sant GR, Fowler FJ, Whitmore KE, SpolarichKroll J. The interstitial cystitis symptom index and problem index. Urology 1997;49:58e63. [8] Lubeck DP, Whitmore K, Sant GR, Alvarez-Horine S, Lai C. Psychometric validation of the O'Leary-Sant interstitial cystitis symptom index in a clinical trial of PentosanPolysulfate sodium. Urology 2001;57:62e6. [9] Ware JE. SF-36 health survey update. Spine 2000:3130e9. [10] Parsons CL, Dell J, Stanford EJ, Bullen M, Kahn BS, Waxell T, et al. Increased prevalence of interstitial cystitis:previously unrecognized urologic and gynecologic cases identified using a new symptom questionnaire and intravesical potassium sensitivity. Urology 2002;60:573e8. [11] Nickel JC, Shoskes D, Irvine-Bird K. Clinical phenotyping of women with interstitial cystitis/painful bladder syndrome:a key to classification and potentially improved management. J Urol 2009;182:155e60. [12] Bogart LM, Suttorp MJ, Elliott MN, Quentin Clemens J, Berry SH. Validation of a quality-of-life scale for women with bladder pain syndrome/interstitial cystitis. Qual Life Res 2012;21:1665e70. [13] Wagenlehner FME, van Till JW, Magri V, Perletti G, Houbiers JG, Weidner W, et al. National Institutes of health chronic prostatitis symptom index (NIH-CPSI) symptom evaluation in multinational cohorts of patients with chronic prostatitis/chronic pelvic pain syndrome. Eur Urol 2013;63:953e9. [14] Hebbar S, Pandey H, Chawla A. Understanding King's Health Questinonnaire (KHQ) in assessment of female urinary incontinence. Int J Res Med Sci 2015;3:531e8. [15] Ahangari A. Prevalence of chronic pelvic pain among women:an updated review. Pain Physician 2014;17:E141e7. [16] Quaghebeur J, Wyndaele JJ. Prevalence of lower urinary tract symptoms and level of quality of life in men and women with chronic pelvic pain. Scand J Urol 2014;49:242e9. [17] Romão AP, Gorayeb R, Romão GS, Poli-Neto OB, dos Reis FJ, Rosa-e-Silva JC, et al. High levels of anxiety and depression have a negative effect on quality of life of women with chronic pelvic pain. Int J Clin Pract 2009;63:707e11. http://dx.doi.org/10.1111/j.1742-1241.2009.02034.x. [18] Rothrock NE, Lutgendorf SK, Kreder JK. Coping strategies in paitents with interstitial cystitis:relationships with quality of life and depression. J Urol 2003;169:233e6. [19] Tripp DA, Nickel JC, Fitzgerald MP, Mayer R, Stechyson N, Hsieh A. Sexual functioning, catastrophizing, depression, and pain as predictors of quality of life in women with interstitial cystitis/painful bladder syndrome. J Urol 2009;730:987e92. [20] Burthick CW. Interstitial cystitis and chronic pelvic pain:new insights in neuropathology, diagnosis, and treatment. Clin Obstet Gynecol 2003;46:811e23. [21] Propert KJ, Mayer R, Nickel JC, Payne CK, Peters KM, Teal V, et al. Followup of patients with interstitial cystitis responsive to treatment with intravesical bacillus calmette-guerin or placebo. J Urol 2007;179:552e5. [22] Tincello D, Walker ACH. Interstitial cystitis in the UK:results of a questionnaire of members of the interstitial cystitis support group. Eur J OB ReprodBiol 2005;118:91e5. [23] Koziol JA, Clark DC, Gittes RF, Tan EM. The natural history of interstitial cystitis:a survey of 374 patients. J Urol 1993;149:465e9. [24] Nickel JC, Payne CK, Forrest J, Lowell Parsons C, Wan GJ, Xiao X. The relationship among symptoms, sleep disturbances, and quality of life in patients with interstitial cystitis. J Urol 2009;181:2555e61. [25] Beckett MK, Elliot MN, Clemens JQ, Ewing B, Berry SH. Consequences of interstitial cystitis/bladder pain symptoms on women's work participation and income:results from National Household Sample. J Urol 2014;19:83e8. [26] Pinto R, Lopes T, Frias B, Silva A, Silva JA, Silva CM, et al. Trigonal injection of botulinum toxin a in patients with refractory bladder pain syndrome/intersitital cystitis. EAU 2010; 58:360e5. [27] Perez-Marrero R, Emerson LE, Feltis JT. A controlled study of dimethylsulfoxideininterstitialcystitis.J Urol1988;140:36e9. [28] Sant GR, LaRock DR. Standard intravesical therapies for interstitial cystitis. Urol Clin N Am 1994;21:73e83. [29] Rössberger J, Fall M, Peeker R. Critical appraisal of dimethyl sulfoxide treatment for interstitial cystitis discomfort, sideeffects and treatment outcome. Scand J Urol Nephrol 2005; 39:73e7. [30] Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006;49:644e50. [31] Payne CK, Mosbaugh PG, Forrest JB, Evans RJ, Whitmore KE, Antoci JP, et al. Intravesical resiniferatoxin for the treatment of interstitial cystitis:a randomized, double-blind, placebo controlled trial. J Urol 2005;173:1590e4. [32] Peeker R, Haghsheno MA, Holmäng S, Fall M. Intravesical Bacillus calmette-guerin and dimethyl sulfoxide for treatment of classic and nonulcer interstitial cystitis:a prospective, randomized double-blind study. J Urol 2000;164:1912e6. [33] Mayer R, Propert KJ, Peters KM, Payne CK, Zhang Y, Burks D, et al. A randomized controlled trial of intravesical bacillus calmette-guerin for treatment refractory interstitial cystitis. J Urol 2005;173:1186e91. [34] Steinhoff G. The efficacy of chondroitin sulfate in treating interstitial cystitis. Eur Urol Suppl 2003;2:14e6. [35] Istek A, Ugurlucan FG, Yasa C, Gokyildiz S, Yalcin O. Randomized trial of long-term effects of percutaneous tibial nerve stimulation on chronic pelvic pain. Arch Gynecol Obstet 2014;290:291e8. [36] Noru T, Fode M, Nordling J. Ileal conduit without cystectomy may be an appropriate option in the treatment of intractable bladder pain syndrome/interstitial cystitis. Scand J Urol 2014; 48:210e5. [37] Dunn M, Ramsden PD, Roberts JBM, Smith JC, Smith PJB. Interstitial cystitis, treated by prolonged bladder distension. BJUI 1977;49:641e5. [38] Badenoch AW. Chronic interstitial cystitis. BJUI 1971;43:718e21. [39] McCahy PJ, Styles RA. Prolonged bladder distension:experience in the treatment of detrusor overactivity and interstitial cystitis. Eur Urol 1995;28:325e7.
Christopher Hartman, Nikhil Gupta, David Leavitt, David Hoenig, Zeph Okeke, Arthur Smith. Advances in percutaneous stone surgery[J]. Asian Journal of Urology, 2015, 2(1): 26
-32
.
